KUALA LUMPUR, Malaysia (AP) — An improvement in China's manufacturing wasn't enough to boost Asian stock markets Thursday after Wall Street fell on disappointing corporate earnings.
U.S. stocks broke a four-day streak of record closes after Caterpillar reported a plunge in third quarter earnings and the falling oil price hurt energy stocks. Caterpillar, which makes mining and construction equipment, is considered an important barometer of the global economy. A weak revenue outlook from communications chip maker Broadcom also weighed on sentiment.
Those cues offset a preliminary HSBC survey showing that China's manufacturing rose to a seven-month high in October, suggesting continued momentum for the rebound in the world's second-biggest economy.
"I feel some of the disappointing earnings were just an excuse for the sell-off," said Stan Shamu, strategist with IG Markets in Australia.
Hong Kong's Hang Seng fell 1 percent to 22,779.33 and China's Shanghai Composite Index was off 0.5 percent at 2,172.03.
Japan's Nikkei 225 shed 0.4 percent to 14,365.50 while Australia's S&P/ASX 200 rose 0.4 percent to 5,375.70.
On Wall Street, the Standard & Poor's 500 fell 0.5 percent to 1,746.38 while the Dow Jones industrial average lost 0.4 percent to 15,413.33.
The S&P had surged 6 percent over the previous two weeks, capped by a record close of 1,754.67 on Tuesday on signs that the Federal Reserve may refrain from pulling back on its economic stimulus until possibly next year.
In energy trading, benchmark U.S. crude for December delivery was up 47 cents at $97.33 a barrel in electronic trading on the New York Mercantile Exchange. The contract fell $1.44 to $96.86 on Wednesday.
The euro rose to $1.3791 from $1.3774 late Wednesday. The dollar dropped to 97.33 yen from 97.36 yen.
Food additive may prevent spread of deadly new avian flu
PUBLIC RELEASE DATE:
23-Oct-2013
[
| E-mail
]
Share
Contact: Sharon Parmet sparmet@uic.edu 312-413-2695 University of Illinois at Chicago
A common food additive can block a deadly new strain of avian influenza virus from infecting healthy cells, report researchers at the University of Illinois at Chicago College of Medicine in the online journal, PLOS ONE.
The compound, in wide use as a preservative, binds to a part of the flu virus that has never been targeted by any existing antiviral drug, raising hopes for its effectiveness against multi-drug-resistant flu viruses.
"The recent H7N9 outbreak in China this past March had a mortality rate of more than 20 percent," says Michael Caffrey, associate professor of biochemistry and molecular genetics at UIC. That strain, which is new, is already showing resistance to the majority of existing drugs used to treat it, Caffrey said. Preventing an outbreak that could lead to mass casualties would be difficult with the current arsenal.
"The need to develop new antiviral therapeutics now is crucial," he said.
Flu viruses enter host cells using a special protein called hemagglutinin, which acts as a "key" that opens receptors on the cell surface. If hemagglutinin is disabled, the virus is locked out and can't infect cells.
UIC researchers, led by Caffrey, found that the FDA-approved food additive tert-butyl hydroquinone sticks to a specific region on the hemagglutinin molecule. The additive, he said, "attaches to the Achilles' heel of the virusa loop-shaped portion of hemagglutinin necessary for binding to cells, making cell infection impossible."
The loop on the hemagglutinin molecule represents a new therapeutic target, since existing drugs don't go after it, Caffrey said.
"Any drugs that focus on the hemagglutinin loop would be totally novel to flu viruses, and so resistance, if developed, would still be a long way off."
Caffrey and his colleagues were looking at a different class of viruses when the first outbreak of the H7N9 virus was reported in China last spring.
"Tert-butyl hydroquinone was known to have virus-blocking effects for H3 viruses," he said. "So when the H7N9 outbreak occurred, we thought we'd see if it had any effect on H7 viruses."
Using a novel technique, the researchers fused the hemagglutinin of the H7N9 virus to a less dangerous virus in order to study it safely. They found that tert-butyl hydroquinone was able to prevent the virus from infecting human lung cells in the lab.
The researchers are now looking for ways to enhance tert-butyl hydroquinone's ability to prevent infection. One way might be to add it to poultry feed. Keeping the virus from spreading in chickens could reduce the likelihood of it jumping to humans, Caffrey said. While the compound is used in a variety of foods as a preservative and stabilizer, questions remain regarding its safety if consumed in very high doses.
###
Coauthors on the PLOS ONE paper, all of UIC, are graduate student Aleksandar Antanasijevic; postdoctoral researcher Han Cheng; Duncan Wardrop, associate professor of chemistry; and Lijun Rong, associate professor microbiology and immunology.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Food additive may prevent spread of deadly new avian flu
PUBLIC RELEASE DATE:
23-Oct-2013
[
| E-mail
]
Share
Contact: Sharon Parmet sparmet@uic.edu 312-413-2695 University of Illinois at Chicago
A common food additive can block a deadly new strain of avian influenza virus from infecting healthy cells, report researchers at the University of Illinois at Chicago College of Medicine in the online journal, PLOS ONE.
The compound, in wide use as a preservative, binds to a part of the flu virus that has never been targeted by any existing antiviral drug, raising hopes for its effectiveness against multi-drug-resistant flu viruses.
"The recent H7N9 outbreak in China this past March had a mortality rate of more than 20 percent," says Michael Caffrey, associate professor of biochemistry and molecular genetics at UIC. That strain, which is new, is already showing resistance to the majority of existing drugs used to treat it, Caffrey said. Preventing an outbreak that could lead to mass casualties would be difficult with the current arsenal.
"The need to develop new antiviral therapeutics now is crucial," he said.
Flu viruses enter host cells using a special protein called hemagglutinin, which acts as a "key" that opens receptors on the cell surface. If hemagglutinin is disabled, the virus is locked out and can't infect cells.
UIC researchers, led by Caffrey, found that the FDA-approved food additive tert-butyl hydroquinone sticks to a specific region on the hemagglutinin molecule. The additive, he said, "attaches to the Achilles' heel of the virusa loop-shaped portion of hemagglutinin necessary for binding to cells, making cell infection impossible."
The loop on the hemagglutinin molecule represents a new therapeutic target, since existing drugs don't go after it, Caffrey said.
"Any drugs that focus on the hemagglutinin loop would be totally novel to flu viruses, and so resistance, if developed, would still be a long way off."
Caffrey and his colleagues were looking at a different class of viruses when the first outbreak of the H7N9 virus was reported in China last spring.
"Tert-butyl hydroquinone was known to have virus-blocking effects for H3 viruses," he said. "So when the H7N9 outbreak occurred, we thought we'd see if it had any effect on H7 viruses."
Using a novel technique, the researchers fused the hemagglutinin of the H7N9 virus to a less dangerous virus in order to study it safely. They found that tert-butyl hydroquinone was able to prevent the virus from infecting human lung cells in the lab.
The researchers are now looking for ways to enhance tert-butyl hydroquinone's ability to prevent infection. One way might be to add it to poultry feed. Keeping the virus from spreading in chickens could reduce the likelihood of it jumping to humans, Caffrey said. While the compound is used in a variety of foods as a preservative and stabilizer, questions remain regarding its safety if consumed in very high doses.
###
Coauthors on the PLOS ONE paper, all of UIC, are graduate student Aleksandar Antanasijevic; postdoctoral researcher Han Cheng; Duncan Wardrop, associate professor of chemistry; and Lijun Rong, associate professor microbiology and immunology.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
HIV-positive babies rest in an orphanage in Nairobi, Kenya. Treatment right after birth may make it possible for HIV-positive newborns to fight off the virus.
Brent Stirton/Getty Images
HIV-positive babies rest in an orphanage in Nairobi, Kenya. Treatment right after birth may make it possible for HIV-positive newborns to fight off the virus.
Brent Stirton/Getty Images
A 3-year-old girl born in Mississippi with HIV acquired from her mother during pregnancy remains free of detectable virus at least 18 months after she stopped taking antiviral pills.
New results on this child, published online by the New England Journal of Medicine, appear to green-light a study in the advanced planning stages in which researchers around the world will try to replicate her successful treatment in other infected newborns.
And it means that the Mississippi girl still can be considered possibly or even probably cured of HIV infection — only the second person in the world with that lucky distinction. The first is Timothy Ray Brown, a 47-year-old American man apparently cured by a bone marrow transplant he received in Berlin a half-dozen years ago.
This new report addresses many of the questions raised earlier this year when disclosure of the Mississippi child's case was called a possible game-changer in the long search for an HIV cure.
"There was some very healthy skepticism," Dr. Katherine Luzuriaga, a professor at the University of Massachusetts in Worcester, tells Shots. She's part of the team that has been exhaustively testing the toddler's blood and considering every possible explanation for her apparently HIV-free state.
Luzuriaga is confident the latest tests prove that the child was truly infected with HIV at the time of her birth — not merely carrying remnants of free-floating virus or infected blood cells transferred before birth from her mother, as some skeptics wondered.
The UMass researcher says there's no way the child's mother could have contributed enough of her own blood plasma to the newborn to account for the high levels of HIV detected in the child's blood shortly after birth.
Similarly, Luzuriaga says, new calculations show that the mother "would have had to transfer a huge number of [HIV-infected] white blood cells to the baby in order for us to get the [viral] signal that we got early on."
Clinching the question as far as the researchers are concerned is the infant's response to anti-HIV drugs that she began receiving shortly after birth. The remarkable earliness of her treatment is a crucial feature that makes this child different from almost any other.
"There's a very characteristic clearance curve of viruses once we start babies on treatment," Luzuriaga says. "The decay of viruses we see in this baby is exactly what we saw in early treatment trials from 20 years ago when we initiated anti-retroviral therapy and shut off viral replication. That's a very different decay curve than you would expect if it were just free virus transferred to the baby."
It might be helpful to recap the unusual, if not unique, features of the Mississippi case.
Her mother did not receive prenatal care, so she was not identified as HIV-infected before delivery. If she had been, she would have received drugs that are highly effective in preventing mother-to-child transmission of the virus.
While the mother was in labor, she got HIV testing, as is routine for women without prenatal care. When that came up positive, Dr. Hannah Gay, a pediatrician at the University of Mississippi Medical Center in Jackson, was ready to test the newborn for infection and start anti-retroviral medicines within 30 hours of birth.
The treatment quickly cleared the virus from the baby's blood. Normally such children would stay on antiviral drugs for a lifetime. But in this case the mother – whose life circumstances were reportedly chaotic – stopped giving the child the medication between 15 and 18 months after birth.
Gay and her colleagues caught up to the child when she was 23 months old and were astonished to discover she was apparently still virus-free despite being off treatment. Five rounds of state-of-the-art testing — at UMass, Johns Hopkins, federal research labs and the University of California San Diego — failed to reveal any trace of the virus in her blood.
That led to last spring's report and widely reported hope that the child had been cured of HIV.
But Dr. Scott Hammer, an HIV researcher at Columbia University in New York, is not quite convinced. "Is the child cured of HIV infection? The best answer at this moment is a definitive 'maybe,' " Hammer writes in a New England Journaleditorial that accompanied the report.
The reason is that a couple of tests done when the child was about 2 years old found indications that her system may contain pieces of RNA or DNA from HIV. This hints that some of the nucleic acid building blocks of the virus are hanging around within her blood cells.
There's no evidence these "proviral" remnants are capable of assembling themselves into whole viruses that can make copies of themselves. But researchers are concerned about that possibility and how it might be headed off.
"The question is whether those viral nucleic acids have the ability at some point to replicate and allow a rebound of the virus," Luzuriaga acknowledges. "That's why it's important to continue to test the baby over time." She says that means years.
But for now, the signs from the Mississippi child's case are encouraging enough to have generated an ambitious global human experiment that Luzuriaga says is in final planning stages.
Women who present in labor without having had prenatal care will be tested for HIV and, if positive, their infants will be intensively treated within a couple of days of birth, as the Mississippi child was. Then they'll be followed with the most sensitive tests to determine if the virus has been eradicated.
If certain criteria are met, researchers plan to decide whether it would be safe to discontinue HIV treatment deliberately and follow the children closely to see if the virus returns. (If it did, treatment would be restarted.)
If the experiment succeeds, it would be a huge advance in the prevention of childhood HIV and AIDS in many parts of the world. More than 9 out of 10 of the world's 3.4 million HIV-infected children live in sub-Saharan Africa, where many women deliver without having had prenatal care or HIV treatment. Around 900 children are newly infected every day.
Meanwhile, researchers pursuing an HIV cure will convene next month in San Francisco to consider various strategies — for adults as well as children. One other recent glimmer of hope was provided this summer by Boston researchers who reported that two HIV-infected men with lymphoma remain virus-free without treatment for several months after stopping antiviral treatment.
SAN FRANCISCO (AP) — LinkedIn just gave its users another reason to ensure their resumes are up to date. The online professional network has introduced a mobile feature that shows information about people's careers in emails being read on iPhones.
The tool, called Intro, pulls details from the profiles of LinkedIn's more than 238 million users so the recipient of an email can learn more about the sender.
The information will be limited to what the email senders already allow anyone to be seen on their LinkedIn accounts, unless they already have granted the recipient broader access through a connection on the service.
The feature released Wednesday works with Gmail, Yahoo Mail, AOL Mail and Apple Inc.'s iCloud when any of them are plugged into the iPhone's built-in email app. LinkedIn Corp. plans to update the feature so it also works with Microsoft Corp.'s Outlook.com and Exchange email. It's available at https://intro.linkedin.com/ .
Intro also works on Apple Inc.'s iPad, although the feature isn't tailored for that device. LinkedIn eventually will release a version of Intro designed especially for the tablet format.
LinkedIn imported the technology powering the Intro feature from its acquisition last year of Rapportive, a startup that had already been mining online social networks to include personal information in correspondence sent to Gmail accounts.
Intro is part of LinkedIn's push to make its network indispensable on mobile devices as more people manage their personal and professional lives on smartphones and tablets.
LinkedIn says about 38 percent of the traffic to it networking services now comes through mobile devices, up from just 8 percent in early 2011. LinkedIn CEO Jeff Weiner predicted Wednesday that mobile devices would be reeling in more than half the service's traffic at some point next year.
As part of its effort to make its network more alluring on mobile, LinkedIn also released a new version of its service's app for the iPad.
LinkedIn's strategy has been paying off since the company went public nearly two-and-half years ago. The Mountain View, Calif. company has consistently been delivering earnings that exceed analyst projections, helping to lift its stock by more than five-fold from its initial public offering price of $45.
The shares shed $3.60 to $241.35 in Wednesday afternoon trading, as the broader markets ticked down..
SAN FRANCISCO (AP) — T-Mobile will give owners of iPads and other tablet computers free data service for life as part of an effort to broaden its customer base beyond phones.
The free service would be limited to 200 megabytes of high-speed data per month —enough to upload about 800 Instagram photos or listen to more than three hours of streaming music, the company said.
T-Mobile US Inc. said the free service comes with no obligations, but the company expects people will want to buy plans for additional data once they grow accustomed to having it.
People typically buy tablet computers that access the Internet using Wi-Fi only. Models with 4G LTE cellular access typically cost $100 to $130 more, but T-Mobile marketing chief Mike Sievert said many people are reluctant to purchase cellular-enabled tablets for fear they would be stuck with monthly data service costs.
By guaranteeing free data service, he said, T-Mobile is hoping to encourage people to buy LTE tablets.
The latest offer, announced Wednesday, comes as the company tries to shatter longstanding industry practices and brand itself as the Un-Carrier.
In March, the company dropped conventional two-year service contracts in favor of selling phones with installment plans. In July, it introduced a program that lets people upgrade phones more frequently — up to twice a year. This month, the company eliminated data and texting fees in more than 100 countries and capped charges for international voice calls.
There are signs the efforts are working. In the April-June quarter, T-Mobile gained long-term, good-credit customers for the first time in at least two and a half years. T-Mobile added a net 688,000 such customers in the quarter, compared with a loss of 557,000 in the same period a year earlier.
The net increase includes 3,000, or less than 0.5 percent, for non-phone service such as tablets. T-Mobile officials believe there's room for further growth.
All tablet computers, including Apple's iPad, Google's Nexus 7 and Amazon's Kindle Fire, are eligible for the offer as long as they work on T-Mobile's network. Sievert said most tablets do.
The new iPads announced Tuesday are universal models, meaning they will work on various LTE networks around the world. Previously, Apple sold separate models compatible with a subset of networks.
Tablet owners will need to buy a SIM card that costs about $10.
T-Mobile said it will sell iPads under installment plans, but people who buy tablets elsewhere will qualify as well.
The free access is limited to the United States.
For $10 a month, T-Mobile phone customers can buy an additional 500 megabytes of high-speed data in the U.S. and unlimited data at slower speeds. That plan also comes with unlimited data at the slower speeds in more than 100 countries. Non-phone customers can pay $20 a month for the same plan. There's no contract, so people can sign up for a month at a time. There are also daily and weekly options.
At rival AT&T, monthly plans start at $15 for 250 megabytes. The company recently introduced $5 day passes, which it says is ideal for travelers looking for an alternative to Wi-Fi hotspots.
LinkedIn’s Jeff Weiner says the barrier to his vision is scale, so it’s beefing up its mobile experience with Intro, an integration adding LinkedIn and Rapportive info to Apple’s Mail app, and a redesigned iPad app. Intro works with Gmail, Yahoo Mail, Aol Mail, iCloud, and Google Apps, and inserting LinkedIn profile photos and job titles below the To/From section of emails in Apple’s Mail app.
Intro is available on an invite only basis starting today but you can sign up here to get access when it’s ready. The app is based on Rapportive, which LinkedIn acquired in February 2012. Rapportive is a desktop app the provides a sidebar of info on who you’re emailing with inside your mail app of choice. Intro brings this same info to the Apple mail app.
The new LinkedIn for iPad app comes out today, and is built to be tablet-specific, not just a website scrammed into a medium-sized screen. It has a personalized navigation carousel at the top and lets you search for companies and jobs, not just people.
Scores of positive reviews repeat the same wording in broken English
BlackBerry's launch of BBM on Android this week was marred by a rather large number — and extremely suspect — reviews left in Google Play along with its 10 million installations on Android and iOS. Apparent to anyone with a set of peepers, the reviews in question all share the same broken English and likely Indonesian origins, though the number of stars left on each review varies.
The reviews read, "Thank you so much blackberry team. I was waiting this app. Its really great user friendly and smooth"
It's still unclear whether the scores and scores of copycat reviews are a coordinated (if ridiculously obvious) effort to game the system, who, exactly, was behind it — as we all know, BlackBerry and BBM have a very ... passionate ... user base — and why the hell they didn't think anyone would notice. To leave a review on an app in Google Play, you have to have a Google+ account. So there are at least names and faces to go with the farce.
BlackBerry's Victoria Berry, director of PR for BBM, gave Android Central the following statement:
We have recently been made aware of a number of potentially fake five-star reviews of BBM for Android on Google Play. We do not approve of or condone such activities and are committed to working with Google to resolve this. There are also many genuinely great and useful reviews from our new BBM users on Google Play. We would like to encourage our passionate fans and users to continue to provide true assessments of the BBM experience through the proper channels.
So, yeah. Something's up. We still don't know exactly why, though.